IPP Bureau
Cipla has strong traction in India and the US: ICICI Direct
By IPP Bureau - January 31, 2022
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Sun Pharma Q3FY22 PAT at Rs 2058.8 cr.
By IPP Bureau - January 31, 2022
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Alkem enters exclusive license agreement with Johns Hopkins University
By IPP Bureau - January 31, 2022
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Foreign Direct Investment in pharma grows at rapid pace: Eco Survey
By IPP Bureau - January 31, 2022
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance
By IPP Bureau - January 30, 2022
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation
By IPP Bureau - January 30, 2022
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
By IPP Bureau - January 29, 2022
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Union minister Mansukh Mandaviya launches NIPER website
By IPP Bureau - January 29, 2022
The aim is to strengthen industry-academia cooperation
Sparsh hospital opens multi-organ transplant centre in Bengaluru
By IPP Bureau - January 29, 2022
The new centre will comprise a team of 50 highly experienced specialists
Israel signs deal to purchase Novavax’ Covid-19 vaccine
By IPP Bureau - January 29, 2022
It would be the first protein-based alternative available in Israel
ARVs bottom out while CRAMS growth continues for Laurus Labs: ICICI Direct
By IPP Bureau - January 29, 2022
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate
By IPP Bureau - January 29, 2022
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
Lupin signs promotional agreement with Exeltis on SOLOSEC
By IPP Bureau - January 28, 2022
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
By IPP Bureau - January 28, 2022
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion
By IPP Bureau - January 28, 2022
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
